Cumberland Pharmaceuticals (CPIX) Liabilities and Shareholders Equity (2016 - 2026)
Cumberland Pharmaceuticals' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $76.8 million for Q4 2025.
- On a quarterly basis, Liabilities and Shareholders Equity rose 1.64% to $76.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $280.6 million, a 10.18% decrease, with the full-year FY2025 number at $76.8 million, up 1.64% from a year prior.
- Liabilities and Shareholders Equity hit $76.8 million in Q4 2025 for Cumberland Pharmaceuticals, up from $65.9 million in the prior quarter.
- Over the last five years, Liabilities and Shareholders Equity for CPIX hit a ceiling of $96.7 million in Q1 2022 and a floor of $65.9 million in Q3 2025.
- Historically, Liabilities and Shareholders Equity has averaged $83.4 million across 5 years, with a median of $86.0 million in 2021.
- Biggest five-year swings in Liabilities and Shareholders Equity: grew 10.02% in 2022 and later fell 14.2% in 2025.
- Tracing CPIX's Liabilities and Shareholders Equity over 5 years: stood at $84.5 million in 2021, then grew by 10.02% to $92.9 million in 2022, then fell by 12.0% to $81.8 million in 2023, then dropped by 7.57% to $75.6 million in 2024, then increased by 1.64% to $76.8 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for CPIX at $76.8 million in Q4 2025, $65.9 million in Q3 2025, and $67.9 million in Q2 2025.